Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Debt Repayments: 2013-2025

Historic Long-Term Debt Repayments for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $44,000.

  • Amphastar Pharmaceuticals' Long-Term Debt Repayments rose 7.32% to $44,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $234,000, marking a year-over-year decrease of 99.60%. This contributed to the annual value of $8.3 million for FY2024, which is 97.41% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Long-Term Debt Repayments of $44,000 as of Q3 2025, which was up 18.92% from $37,000 recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Long-Term Debt Repayments high stood at $200.1 million for Q3 2023, and its period low was $37,000 during Q2 2025.
  • In the last 3 years, Amphastar Pharmaceuticals' Long-Term Debt Repayments had a median value of $115,000 in 2024 and averaged $29.7 million.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first spiked by 39,081.25% in 2023, then tumbled by 99.98% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Long-Term Debt Repayments (Quarterly) stood at $613,000 in 2021, then tumbled by 79.12% to $128,000 in 2022, then surged by 39,081.25% to $50.2 million in 2023, then plummeted by 99.77% to $115,000 in 2024, then increased by 7.32% to $44,000 in 2025.
  • Its Long-Term Debt Repayments stands at $44,000 for Q3 2025, versus $37,000 for Q2 2025 and $38,000 for Q1 2025.